Status:
WITHDRAWN
Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Conditions:
Covid-19
Anosmia
Eligibility:
All Genders
18+ years
Brief Summary
To date there is no brain imaging and olfactory data available in COVID-19 positive patients with anosmia. By describing the pathophysiological characteristics underlying the olfactory symptoms and cl...
Detailed Description
Brain mapping of COVID-19 patients with or without anosmia will allow better understanding of the mechanisms leading to the onset of these symptoms and will provide a pathophysiological basis for the ...
Eligibility Criteria
Inclusion
- Consecutive adult patients consulting the CAREB or hospitalized at the Nîmes teaching hospital due to COVID-19 infection (fever, persistent cough, tiredness, shortness of breath, diarrhea, abdominal pain, chest pain, sore throat, loss of smell or taste)
- COVID-19 confirmed by RT-PCR and / or chest CT or clinical characteristics (i.e an epidemic history and 2 clinical manifestations or at least 3 clinical manifestations)
- The patient must have given their free and informed consent and signed the consent form
- The patient must be a member or beneficiary of a health insurance plan "with anosmia" group:
- scoring \< 30 on a VAS 0-100 for olfactory ability
- Responding "yes" to question "have you lost your sense of smell in the last few days?"
- Negative result to olfactory test with n-Butanol diluted to 1/1000. "without anosmia" group:
- scoring \< 80 on a VAS 0-100 for olfactory ability
- Responding "no" to question "have you lost your sense of smell in the last few days?"
- Positive result to olfactory test with n-Butanol diluted to 1/16000.
Exclusion
- Patient suffering from serious medical problems or hospitalized in an intensive care unit for invasive ventilation or severe dyspnea.
- Patient with neurological (motor, sensitive or cognitive), neuropsychiatric or vascular disorders.
- Patient with a contraindication to MRI (pace maker, claustrophobic patient, metallic heart valve, etc.).
- Patient with a history of rhinological pathology or a sense of smell problem.
- Patient with known neurological, psychiatric or neuroradiological manifestation.The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study
- The subject is unable to express consent
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
- Patient is pregnant, parturient or breastfeeding
Key Trial Info
Start Date :
May 20 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 6 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04408391
Start Date
May 20 2020
End Date
July 6 2020
Last Update
August 5 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nimes
Nîmes, France